

Thermo Fisher unveils high-throughput solution to test 8k COVID-19 samples daily

09 February 2021 | News

Applied Biosystems TaqPath COVID-19 High Throughput Combo Kit also receives Interim Order Authorization from Health Canada



Thermo Fisher Scientific, the world leader in serving science, launched its CE-IVD-Marked, Applied Biosystems TaqPath COVID-19 HT Kit that is compatible with the Amplitude platform. The high-throughput solution enables clinical and public health laboratories to efficiently test up to 8,000 COVID-19 samples a day with fewer staffing requirements and a reliable supply of kits, reagents and consumables.

The highly automated Amplitude platform is a molecular diagnostic system that allows labs to increase their COVID-19 testing capacity by combining Thermo Fisher's extraction and real-time PCR instruments with liquid handling products from Tecan Group. The system leverages a high-throughput version of Thermo Fisher's TaqPath COVID-19 CE-IVD RT-PCR Kit, which received CE-IVD Mark in March 2020.

The high throughput diagnostic assay, compatible with the Amplitude platform, also received interim order authorisation from Health Canada on January 21.

Mark Smedley, President, Genetic Sciences Business, Thermo Fisher Scientific said, "The Amplitude platform embodies our goal of empowering public health and clinical lab professionals to generate accurate results at higher volumes and use them to make informed healthcare decisions that lead to the management of a pandemic that is still raging around the world."

With the Amplitude platform, customers receive a reliable supply agreement and up-front monthly delivery of reagents to ensure that COVID-19 testing needs are met. Thermo Fisher now has capacity to produce more than 20 million tests per week and continues to work closely with laboratories, governments, academic institutions and other stakeholders to ensure each has a reliable supply of tests and materials.